03/12/2020

Emyria sees strong interest in IBS study, launches second drug development program

Highlights:

- **Emyria has received strong interest in its CALM-GUT Study from potential participants**
- **Up to 200 people will be included in the study, expected to last 12 months**
- **Emyria is undertaking this observational study as an important step towards generating evidence of efficacy and safety for routinely prescribed medicinal cannabis for the management of symptoms in patients with irritable bowel syndrome (IBS), a significant unmet medical need**
- **This study will also inform the development of EMD-004, Emyria's second cannabinoid-based drug candidate**
- **Prof Alistair Vickery and specialist gastroenterologist Dr Chris Schneider are leading the study across Victoria, NSW and Western Australia**
- **Recruitment is ongoing for this ethics-approved study**
- **Emyria's managing director, Dr Michael Winlo, will speak on Emyria's growing product development portfolio at "TechKnow Invest Perth" on December 8th - registration details below**

Emyria Limited (ASX: EMD) (Emyria or the Company), a company that accelerates treatment development for patients with unmet needs based on its Real-World Evidence (RWE) insights, is pleased to announce strong interest from potential participants for an Emyria-led study into irritable bowel syndrome (IBS).

IBS affects around 11% of the population globally and is a significant unmet need often associated with greater levels of anxiety and lower quality of life measures.*

Emyria decided to launch the study following in-depth analysis of it's Real World Evidence (RWE) data asset on IBS patients cared for at Emyria's clinical subsidiary Emerald Clinics (www.emeraldclinics.com.au). The CALM-GUT study will inform Emyria's general care program for IBS patients and also Emyria's second drug development program to be called EMD-004.

EMD-004 will compliment Emyria's recent mental health focussed drug development program - EMD-003 - which is also backed by Emyria's RWE (see ASX release 25 NOV 20).

Emyria's drug development programs encompass unique clinical evidence packages, intellectual property (IP) and strategically developed clinical trial protocols informed by Emyria's unique Real-World Evidence (RWE) and observational trial results. The development programs are intended to support the registration of specific medicines for specific health indications with the Therapeutic Goods Administration's (TGA) Australian Register of Therapeutic Goods (ARTG).

Emyria's Managing Director, Dr Michael Winlo, said: "*We're pleased to see strong interest in our CALM-GUT study from patients with irritable bowel syndrome. IBS can be a challenging condition to manage and the strong interest demonstrates the need for safe and effective options. We were encouraged to initiate this study based on an analysis of our Real-World Evidence and have designed it to support our second drug development program - EMD-004. This study will also inform how we can better care for patients with this condition and we're very pleased to be collaborating with Dr Chris Schneider, a consultant gastroenterologist based in Melbourne, on these projects.*"

For more details on CALM-GUT, interested potential participants can visit https://www.emeraldclinics.com.au/clinical-trials

* https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921083/

TechKnow Invest
Dr Michael Winlo will present on the company's product development pipeline and launch strategy at TechKnow Perth.

Details of the event are as follows:

Event: Techknow Invest Perth
Presenters: Michael Winlo, Managing Director
Time: Tuesday 8th December 2020, 2:00 pm (AWDT)
Where: Ritz Carlton Perth WA
To register to attend in-person (Free): https://tkperth.eventbrite.com.au

To register to the live streaming via zoom (Free), please click through to the link below:
https://techknowperthlivestreaming.eventbrite.com.au

This announcement has been approved and authorised for release by the Board of Emyria Limited.

For further information:

Dr Michael Winlo
Managing Director
(08) 6559 2800
mwinlo@emyria.com

Lexi O'Halloran
Media/Investor Relations
+ 61 (0) 404 577 076
lexi@janemorganmanagement.com.au

About Emyria (www.emyria.com)
Emyria Limited creates drug development programs for patients with unmet needs. These programs can be progressed by partners or independently. Emyria is uniquely placed to accomplish this by managing an independent specialist clinical network – Emerald Clinics (www.emeraldclinics.com.au) and by building bespoke remote patient monitoring technologies and clinical-trial-grade data platforms. Emyria uses these resources to turn its proprietary clinical data into Real World Evidence (RWE) and unique IP. Emyria's RWE is the backbone of its patient care and drug development programs and provides insights into the safety, quality and efficacy of unapproved treatments, in real patients, in the community. Emyria RWE can greatly accelerate the registration of new treatments. Registered treatments can become available to a much wider population of patients via routine prescription pathways creating great value. Recently, Emyria announced the launch of its own drug development program to register new treatments for the growing challenge of mental health.

Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.